ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CRDF vs PTHS // RETURN ON INVESTED CAPITAL (ROIC)

Cardiff Oncology Inc. (NASDAQ) VS. Pelthos Therapeutics Inc. (NYSE) • 15-METRIC TALLY: CRDF 3 — PTHS 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRDF VS. PTHS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CRDF PTHS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 76.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -7.70% -60.00% +52.30 CRDF /net-margins <GO>
Revenue Growth (YoY) -13.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 PTHS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.9 21.8 +17.02 CRDF /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $70.9M $63.3M $7.6M CRDF /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CRDF REV PTHS REV CRDF GROSS % PTHS GROSS % CRDF FCF PTHS FCF
FY 2025 $593.0K $16.8M — 76.3% -$38.0M -$22.7M
FY 2024 $683.0K $0 — — -$37.8M -$5.8M
FY 2023 $488.0K $0 — — -$30.9M -$981.0K
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRDF // BETA —
PTHS // BETA —